Various drugs used in the treatment of either allergy or inflammation have been studied in the rat. Prausnitz-Küstner (PK) type reactions, passive cutaneous anaphylaxis (PCA) and peritoneal mast cell degranulation (MCD) were used as models of type I anaphylactic hypersensitivity. In the PK test, the rank order of potency of the drugs tested was isoprenaline > PGF2α > disodium cromoglycate (DSCG) > indomethacin > theophylline. In the PCA test, the rank order was similar, although the difference between the potencies of DSCG and indomethacin was greater here than in the PK reaction. Dibutyryl cyclic AMP was inactive in both forms of cutaneous anaphylaxis. Noradrenaline, imidazole and propranolol induced MCD. Marked inhibition of phospholipase-A-induced degranulation occurred in the presence of DSCG, theophylline, indomethacin, dibutyryl cyclic AMP, aspirin, propranolol and phentolamine. Isoprenaline and prostaglandins E1; E2 and A1 all slightly inhibited MCD over a wide range of concentrations. Isoprenaline was synergistic with DSCG and theophylline in both PCA and MCD, and PGE1 was synergistic with both DSCG and theophylline in MCD. However, there was no synergism between DSCG and theophylline or between isoprenaline and PGE1. The role of cyclic AMP in allergic reactions of the rat is discussed as is the mode of action of DSCG.

This content is only available via PDF.
© 1974 S. Karger AG, Basel
1974
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.